/ Not yet recruitingPhase 1 Phase I Open-label, First-in-human Study to Evaluate Feasibility and Safety of Tissue Engineered Veins in Patients With Chronic Venous Insufficiency
This study aims to evaluate the safety (incidence of adverse events including serious adverse events and clinical significant laboratory abnormalities) of personalized tissue engineered veins (P-TEV) with valves implanted in patients with severe chronic venous insufficiency (CVI). For each patient a segment of the femoral vein containing the non-functioning valve will be surgically replaced with a single P-TEV containing a functioning valve.
100 Clinical Results associated with Verigraft AB
0 Patents (Medical) associated with Verigraft AB
100 Deals associated with Verigraft AB
100 Translational Medicine associated with Verigraft AB